Timmons Joshua J, Zhang Kisa, Fong Johnson, Lok Edwin, Swanson Kenneth D, Gautam Shiva, Wong Eric T
Brain Tumor Center & Neuro-Oncology Unit, Department of Neurology.
Biostatistics Section, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA.
Am J Clin Oncol. 2018 Dec;41(12):1281-1287. doi: 10.1097/COC.0000000000000434.
This systematic review aims to investigate spinal cord glioblastoma (scGBM) and correlations between patient traits and survival outcome, as well as differences in cohorts administered temozolomide or total resections, through an analysis of published cases reported up to October 2016.
We obtained patient data by querying PubMed and Google Scholar with predetermined search terms and inclusion criteria that enabled the identification of relevant case reports. Survival was compared using Kaplan-Meier curves and log-rank analyses.
Of 153 patients with scGBM identified through a literature search, 135 met the predetermined search and inclusion criteria. Median overall survival (OS) for the resulting cohort was 12 (95% CI, 10-14) months. The female sex was found to significantly predict worse outcomes, and a sizable number of patients with long-term disease were found to have afflictions of the thoracic spinal cord. Neither the pediatric, temozolomide nor total resection subgroups had significantly improved survival characteristics, by log-rank analysis, relative to counterparts.
These data elucidate the characteristics of patients with scGBM. For more sophisticated and in-depth analyses in the future, it is imperative that time-of-treatment information is recorded in future case reports. In addition, all case reports should be made available to prevent publication bias.
本系统评价旨在通过分析截至2016年10月发表的病例报告,研究脊髓胶质母细胞瘤(scGBM)以及患者特征与生存结果之间的相关性,以及接受替莫唑胺治疗或全切除的队列之间的差异。
我们通过使用预定的搜索词和纳入标准查询PubMed和谷歌学术来获取患者数据,这些搜索词和纳入标准能够识别相关的病例报告。使用Kaplan-Meier曲线和对数秩分析比较生存率。
通过文献检索确定的153例scGBM患者中,135例符合预定的搜索和纳入标准。该队列的中位总生存期(OS)为12(95%CI,10-14)个月。发现女性显著预示预后较差,并且发现相当数量的长期患病患者患有胸段脊髓疾病。通过对数秩分析,儿科、替莫唑胺或全切除亚组相对于对应亚组均未显示出生存特征有显著改善。
这些数据阐明了scGBM患者的特征。为了未来进行更复杂和深入的分析,必须在未来的病例报告中记录治疗时间信息。此外,应提供所有病例报告以防止发表偏倚。